Veracyte officer sells 13,425 shares in plan trade
Veracyte, Inc. executive Phillip G. Febbo reported two stock transactions on March 2, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Veracyte, Inc. executive Phillip G. Febbo reported two stock transactions on March 2, 2026. The company withheld 6,035 shares of common stock at $36.01 per share to cover his tax obligations from vesting restricted stock units, which is not a market sale. He also completed an open-market sale of 13,425 shares at a weighted average price of $36.1586 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly owned 117,346 shares of Veracyte common stock.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise Price or Tax Liability | Common Stock | 6,035 | $36.01 | $217K |
| Sale | Common Stock | 13,425 | $36.1586 | $485K |
Footnotes (3)
- F1. Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on March 2, 2026 and does not represent a sale.
- F2. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025.
- F3. Represents weighted average sales price. Sale prices for the transactions range from $35.78 to $36.65. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Veracyte (VCYT) report for Phillip G. Febbo?
Was the Veracyte (VCYT) insider sale made under a Rule 10b5-1 plan?
What is the nature of the ‘F’ code transaction in this Veracyte (VCYT) filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.